Cg Oncology, Inc. · NASDAQ:CGON
Cg Oncology — NCSAUA Annual Meeting 2025
11 slides from Cg Oncology's conference presentation, Oct 16, 2025
Slide 1: Updates to CORE-008: A Phase 2 Multi-Arm, Multi-Cohort Study of Cretostimogene in HR NMIBC
Updates to CORE-008: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk Non-Muscle Invasive Bladder Cancer For individual reference only. The information accessed through this QR code is intended solely Gary D. Steinberg, MD for
Slide 2: Disclosures
Disclosures • CG Oncology – No conflict of interest
Slide 3: Oncolytic Immunotherapy: Chain Reaction of Cancer Cell Death
Oncolytic Immunotherapy: Chain Reaction of Cancer Cell Death: Cretostimogene Grenadenorepvec's Dual Viral progeny spread to additional Mechanism of Action tumor cells ») Selectively Replicates in and / Lyses Bladder Cancer Cells (2 \ Simultaneously Amplifies Innate to Adaptive Immune Switch: \&/ Ant
Slide 4: Considerable Unmet Needs in High-Risk NMIBC
Considerable Unmet Needs in High-Risk NMIBC • Guidelines currently recommend IVE BCG or radical cystectomy • Challenges with BCG o Despite high initial response rates, over 50% of patients will recur1 o 20-40% are at risk for progression2,3 o Ongoing BCG shortages4 • Risks with radical cystectomy o
Slide 5: Broad High-Risk NMIBC Study Population
Broad High-Risk* NMIBC Study Population * High-Risk NMIBC eligibility per AUA/SUO guideline criteria 5 Roumiguié M, Kamat AM, Bivalacqua TJ, et al. Eur Urol. 2022 Jul;82(1):34-46. doi: 10.1016/j.eururo.2021.12.005. Epub 2021 Dec 23.
Slide 6: Cretostimogene Grenadenorepvec in High-Risk NMIBC
Phase 2, Multi-Cohort, Open-Label Study of Cretostimogene Grenadenorepvec in High-Risk NMIBC Key Secondary Endpoints Duration of Response All-Cause Event Free Survival Bladder Cancer Specific Survival Cystectomy-Free Survival Safety Tolerability CORE-008 will investigate cretostimogene as monotherap
Slide 7: Cohort CX: Possible Synergism Between Cretostimogene & Gemcitabine
Cohort CX: Possible Synergism Between Cretostimogene & Gemcitabine Cretostimogene • Efficacy, safety, and tolerability Gemcitabine demonstrated as monotherapy and in combination Oncolysis • Pre-clinical synergy with gem and oncolytic immunotherapy in other tumor ✓ Release of cytokine/antigen types ✓
Slide 8: Treatment & Assessment Schedule
Treatment & Assessment Schedule Legend IVE creto IVE gem • Cystoscopy & Cytology every 3 months • CT/MRU every 6 months • Re-induction allowed for patients with HG Ta and/or CIS at Month 3 • Treatment is optional in Year 3 8
Slide 9: Key Eligibility Criteria
Key Eligibility Criteria Exclusion Criteria • MIBC, Nodal or Metastatic UC • UC in upper tract or urethra within 24 months Inclusion Criteria • Any history of T3 or higher in upper tract/T2 within 4 years • HR NMIBC, AUA definition • Prior systemic treatment, radiation, or surgery (beyond • BCG-naïv
Slide 10: CORE-008 is Currently Ongoing & Actively Enrolling
CORE-008 is Currently Ongoing & Actively Enrolling • As of October 2025: o Cohort A (BCG-Naïve) - CIS containing arms have completed enrollment - HG Ta/T1 arm planned o Cohort B (BCG-Exposed) is planned and received collaborative SUO-CTC support o Cohort CX (BCG-Exposed & BCG- UR)- completed enrollm
Slide 11: Thank You
Thank You All Bladder Cancer Patients and Their Families Key Investigators, Study Coordinators, Nurses Key Collaborators CG Oncology For individual reference only. The information accessed through this QR code is intended solely for individual Trinity Bivalacqua, UP, PA Andy Darilek reference and sh